Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy

mTOR Signaling in Growth, Metabolism, and Disease

Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555 · see citing works

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · see citing works

Comprehensive molecular profiling of lung adenocarcinoma

The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732 · see citing works

Discovery and saturation analysis of cancer genes across 21 tumour types

Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096 · cited 1× · see citing works

Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · see citing works

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445 · see citing works

Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery

Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,183 · see citing works

The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism

Hoxhaj, G., & Manning, B. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0216-7 · Cited by 2,137 · see citing works

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism

Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043 · see citing works

Targeting PI3K/Akt signal transduction for cancer therapy

He, Y., Sun, M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,996 · see citing works

The emerging mechanisms of isoform-specific PI3K signalling

Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767 · see citing works

Targeting PI3K in cancer: mechanisms and advances in clinical trials

Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,540 · see citing works

Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539 · see citing works

PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting

Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3860 · Cited by 1,365 · see citing works

Signalling through the lipid products of phosphoinositide-3-OH kinase

Toker, A., & Cantley, L. C. (1997) · Nature · doi:10.1038/42648 · Cited by 1,314 · see citing works

The updated landscape of tumor microenvironment and drug repurposing

Jin, M.-Z., & Jin, W.-L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00280-x · Cited by 1,262 · see citing works

PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside

Alzahrani, A. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.009 · Cited by 1,063 · see citing works

The evolutionary history of 2,658 cancers

Gerstung, M., Jolly, C., Leshchiner, I., Dentro, S. C., Gonzalez, S., Rosebrock, D., Mitchell, T. J., Rubanova, Y., Anur, P., Yu, K., et al. (2020) · Nature · doi:10.1038/s41586-019-1907-7 · Cited by 1,057 · see citing works

An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.

Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054 · see citing works

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · see citing works

Targeting the PI3K pathway in cancer: are we making headway?

Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033 · see citing works

Glucose Deprivation Contributes to the Development of <i>KRAS</i> Pathway Mutations in Tumor Cells

Yun, J., Rago, C., Cheong, I., Pagliarini, R., Angenendt, P., Rajagopalan, H., Schmidt, K., Willson, J. K. V., Markowitz, S., Zhou, S., et al. (2009) · Science · doi:10.1126/science.1174229 · Cited by 914 · see citing works

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873 · see citing works

mTOR Controls Cell Cycle Progression through Its Cell Growth Effectors S6K1 and 4E-BP1/Eukaryotic Translation Initiation Factor 4E

Fingar, D. C., Richardson, C. J., Tee, A. R., Cheatham, L. A., Tsou, C., & Blenis, J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.24.1.200-216.2004 · Cited by 865 · see citing works

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

Junttila, T. T., Akita, R. W., Parsons, K. L., Fields, C. T., Phillips, G. D. L., Friedman, L. S., Sampath, D., & Sliwkowski, M. X. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.020 · Cited by 829 · see citing works

The PI3K/AKT Pathway as a Target for Cancer Treatment

Mayer, I. A., & Arteaga, C. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-062913-051343 · Cited by 826 · see citing works

Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition

Sun, S., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 800 · see citing works

Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.

Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785 · see citing works

Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma.

Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 772 · see citing works

Targeting mTOR for cancer therapy

Hua, H., Kong, Q.-B., Zhang, H., Wang, J., Luo, T., & Jiang, Y.-F. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0754-1 · Cited by 772 · see citing works

The Identification of 2-(1 H -Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d ]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Folkes, A. J., Ahmadi, K., ALDERTON, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I., Clarke, P. A., Depledge, P., Eccles, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800295d · Cited by 756 · see citing works

Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance

Ediriweera, M. K., Tennekoon, K. H., & Samarakoon, S. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.012 · Cited by 752 · see citing works

Mammalian target of rapamycin: a central node of complex signaling cascades.

Dobashi, Y., Watanabe, Y., Miwa, C., Suzuki, S., & Koyama, S. (2011) · PubMed Central · Cited by 721 · see citing works

Suppression of insulin feedback enhances the efficacy of PI3K inhibitors

Hopkins, B. D., Pauli, C., Du, X., Wang, D. G., Li, X., Wu, D., Amadiume, S. C., Goncalves, M. D., Hodakoski, C., Lundquist, M. R., et al. (2018) · Nature · doi:10.1038/s41586-018-0343-4 · Cited by 706 · see citing works

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

Steelman, L. S., Chappell, W. H., Abrams, S. L., Kempf, C., Long, J. M., Laidler, P. M., Mijatović, S., Maksimović‐Ivanić, D., Stivala, F., Mazzarino, M. C., et al. (2011) · Aging · doi:10.18632/aging.100296 · Cited by 689 · see citing works

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Bendell, J. C., Rodon, J. A., Burris, H. A., de Jonge, M. J. A., Verweij, J., Birle, D. C., Demanse, D., Buck, S. S. D., Ru, Q. C., Peters, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 687 · see citing works

PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives

Asati, V., Mahapatra, D. K., & Bharti, S. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.012 · Cited by 618 · see citing works

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres‐Lockhart, K., Prat, A., Antón, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 609 · see citing works

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy

Tian, T., Li, X., & Zhang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030755 · Cited by 581 · see citing works

Role of PI3K/AKT pathway in cancer: the framework of malignant behavior

Jiang, N., Dai, Q., Su, X., Fu, J., Feng, X., & Peng, J. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05435-1 · Cited by 577 · see citing works

ErbB receptors: from oncogenes to targeted cancer therapies

Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J. A., Murali, R., & Greene, M. I. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32278 · Cited by 573 · see citing works

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer

Miller, T. W., Hennessy, B. T., Gonzalez-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., Garcı́a-Echeverrı́a, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 555 · see citing works

PTEN-deficient cancers depend on PIK3CB

Wee, S., Wiederschain, D., Maira, S.-M., Loo, A. T., Miller, C., deBeaumont, R. S., Stegmeier, F. P., Yao, Y.-M., & Christoph Lengauer, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802655105 · Cited by 545 · see citing works

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

Herman, S. E. M., Gordon, A. L., Wagner, A. J., Heerema, N. A., Zhao, W., Flynn, J. M., Jones, J. J., Andritsos, L. A., Puri, K. D., Lannutti, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271171 · Cited by 544 · see citing works

Oncogenic K‐Ras decouples glucose and glutamine metabolism to support cancer cell growth

Gaglio, D., Metallo, C. M., Gameiro, P. A., Hiller, K., Danna, L. S., Balestrieri, C., Alberghina, L., Stephanopoulos, G., & Chiaradonna, F. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.56 · Cited by 492 · see citing works

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

Jiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J., & Hodi, F. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2731 · Cited by 485 · see citing works

mTOR: Role in cancer, metastasis and drug resistance

Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.003 · Cited by 483 · see citing works

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Davies, B. R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.-H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0824-t · Cited by 480 · see citing works

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Kim, S., Dent, R. A., Im, S., Espié, M., Blau, S. H., Tan, A. R., Isakoff, S. J., Oliveira, M., Saura, C., Wongchenko, M. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30450-3 · Cited by 478 · see citing works

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

Hoeflich, K. P., O'Brien, C. L., Boyd, Z. S., Cavet, G., Guerrero, S., Jung, K., Januario, T., Savage, H. M., Punnoose, E. A., Truong, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0317 · Cited by 467 · see citing works

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer

Miller, T. W., Rexer, B. N., Garrett, J. T., & Arteaga, C. L. (2011) · Breast Cancer Research · doi:10.1186/bcr3039 · Cited by 465 · see citing works

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J. J., Spratt, D. E., Viola, N. T., Castel, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4442 · Cited by 432 · see citing works

4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors

She, Q.-B., Halilovic, E., Ye, Q., Zhen, W., Shirasawa, S., Sasazuki, T., Solit, D. B., & Rosen, N. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.023 · Cited by 400 · cited 1× · see citing works

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer

Dong, C., Wu, J., Chen, Y., Nie, J., & Chen, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.628690 · Cited by 383 · see citing works

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux

O’Donnell, J. S., Massi, D., Teng, M. W. L., & Mandalà, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.015 · Cited by 382 · see citing works

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Leo, A. D., Johnston, S. R. D., Lee, K. S., Ciruelos, E., Lønning, P. E., Janni, W., O'Regan, R. M., Mouret‐Reynier, M., Kalev, D. N., Egle, D., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30688-5 · Cited by 382 · see citing works

Classes of phosphoinositide 3-kinases at a glance

Jean, S., & Kiger, A. A. (2014) · Journal of Cell Science · doi:10.1242/jcs.093773 · Cited by 380 · see citing works

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Sarker, D., Ang, J. E., Baird, R. D., Kristeleit, R. S., Shah, K. J., Moreno, V., Clarke, P. A., Raynaud, F. I., Levy, G. G., Ware, J. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0947 · Cited by 361 · see citing works

Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair

Saal, L. H., Gruvberger-Saal, S. K., Persson, C., Lövgren, K., Jumppanen, M., Staaf, J., Jönsson, G. B., Pires, M. M., Maurer, M., Holm, K., et al. (2007) · Nature Genetics · doi:10.1038/ng.2007.39 · Cited by 357 · see citing works

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer

Mayer, I. A., Abramson, V. G., Formisano, L., Balko, J. M., Estrada, M. V., Sanders, M. E., Juric, D., Solit, D. B., Berger, M. F., Won, H. H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0134 · Cited by 320 · see citing works

Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis

Schrijver, W. A. M. E., Suijkerbuijk, K. P. M., van Gils, C. H., van der Wall, E., Moelans, C. B., & van Diest, P. J. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx273 · Cited by 312 · see citing works

Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

Lin, J. M., Sampath, D., Nannini, M., Lee, B. B., Degtyarev, M. Y., Oeh, J., Savage, H. M., Guan, Z., Hong, R., Kassees, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3072 · Cited by 295 · see citing works

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

Mishra, R., Patel, H. M., Alanazi, S., Kilroy, M. K., & Garrett, J. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073464 · Cited by 292 · see citing works

Phosphatidylinositol 3‐phosphates—at the interface between cell signalling and membrane traffic

Marat, A. L., & Haucke, V. (2016) · The EMBO Journal · doi:10.15252/embj.201593564 · Cited by 285 · see citing works

Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers

Fedele, C. G., Ooms, L. M., Ho, M., Vieusseux, J. L., O'Toole, S. A., Millar, E. K. A., López‐Knowles, E., Sriratana, A., Gurung, R., Baglietto, L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015245107 · Cited by 283 · see citing works

Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease

Burke, J. E. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.08.005 · Cited by 276 · see citing works

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Bairi, K. E., Haynes, H. R., Blackley, E. F., Fineberg, S., Shear, J., Turner, S., de Freitas, J. R., Sur, D. G., Amendola, L. C., Gharib, M., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00346-1 · Cited by 271 · see citing works

The Role of mTOR Signaling as a Therapeutic Target in Cancer

Popova, N. V., & Jücker, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041743 · Cited by 267 · see citing works

PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer

Song, M., Chen, D., Lu, B., Wang, C., Zhang, J., Huang, L., Wang, X., Timmons, C. L., Hu, J., Liu, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065821 · Cited by 266 · see citing works

Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy

Okkenhaug, K., Graupera, M., & Vanhaesebroeck, B. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0716 · Cited by 264 · see citing works

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

Liu, N., Rowley, B. R., Bull, C. O., Schneider, C., Haegebarth, A., Schatz, C. A., Fracasso, P. R., Wilkie, D. P., Hentemann, M. F., Wilhelm, S. M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0993-t · Cited by 263 · see citing works

Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer

Niederst, M. J., & Engelman, J. A. (2013) · Science Signaling · doi:10.1126/scisignal.2004652 · Cited by 261 · see citing works

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics

Akinleye, A., Avvaru, P., Furqan, M., Song, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-88 · Cited by 259 · see citing works

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

O'Brien, C. L., Wallin, J. J., Sampath, D., GuhaThakurta, D., Savage, H. M., Punnoose, E. A., Guan, J., Berry, L., Prior, W. W., Amler, L. C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2828 · Cited by 256 · see citing works

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors

Hanker, A. B., Kaklamani, V., & Arteaga, C. L. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1175 · Cited by 256 · see citing works

Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer

Juric, D., Jankú, F., Rodon, J. A., Burris, H. A., Mayer, I. A., Schüler, M., Seggewiß-Bernhardt, R., Gil-Martín, M., Middleton, M. R., Baselga, J. M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4475 · Cited by 247 · see citing works

Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition

Hoeflich, K. P., Merchant, M., Orr, C., Chan, J., Den Otter, D., Berry, L., Kasman, I., Koeppen, H., Rice, K., Yang, N.-Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1515 · Cited by 242 · see citing works

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

Jones, R. H., Casbard, A. C., Carucci, M., Cox, C., Butler, R., Alchami, F., Madden, T., Bale, C. J., Bezecny, P., Joffe, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30817-4 · Cited by 235 · see citing works

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer

Li, H., Prever, L., Hirsch, E., & Gulluni, F. (2021) · Cancers · doi:10.3390/cancers13143517 · Cited by 229 · see citing works

Inhibition of Phosphatidylinositol-3-OH Kinase/Akt Signaling Impairs DNA Repair in Glioblastoma Cells following Ionizing Radiation

Kao, G. D., Jiang, Z., Fernandes, A. M., Gupta, A., & Maity, A. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703042200 · Cited by 225 · see citing works

PI3K Inhibitors in Breast Cancer Therapy

Ellis, H., & Ma, C. X. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0846-7 · Cited by 220 · see citing works

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer

Papadimitrakopoulou, V. A. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31825493eb · Cited by 218 · see citing works

PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells

Zheng, W., O'Hear, C. E., Alli, R., Basham, J. H., Abdelsamed, H. A., Palmer, L. E., Jones, L. L., Youngblood, B., & Geiger, T. L. (2018) · Leukemia · doi:10.1038/s41375-017-0008-6 · Cited by 214 · see citing works

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

Britten, C. D. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2121-1 · Cited by 212 · see citing works

PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer

Li, H., Zeng, J., & Shen, K. (2014) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-014-3377-3 · Cited by 203 · see citing works

Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity

Ndubaku, C. O., Heffron, T. P., Staben, S. T., Baumgardner, M., Blaquière, N., Bradley, E. K., Bull, R., Do, S., Dotson, J., Dudley, D. A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4003632 · Cited by 182 · see citing works

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

Martín, M., Chan, A., Dirix, L. Y., O’Shaughnessy, J., Hegg, R., Manikhas, A., Shtivelband, M. I., Криворотько, П. В., López, N. B., Campone, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw562 · Cited by 180 · see citing works

Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

Mayer, I. A., Abramson, V. G., Isakoff, S. J., Forero, A., Balko, J. M., Kuba, M. G., Sanders, M. E., Yap, J. T., den Abbeele, A. D. V., Li, Y., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0518 · Cited by 176 · see citing works

PI3K-C2γ is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling

Braccini, L., Ciraolo, E., Campa, C. C., Perino, A., Longo, D. L., Tibolla, G., Pregnolato, M., Cao, Y., Tassone, B., Damilano, F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8400 · Cited by 175 · see citing works

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

Saura, C., Roda, D., Roselló, S., Oliveira, M., Macarulla, T. M., Fidalgo, J. A. P., Morales‐Barrera, R., Sanchis, J. M., Musib, L. C., Budha, N. R., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0512 · Cited by 173 · see citing works

Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis

Ocaña, A., Vera-Badillo, F., Al-Mubarak, M., Templeton, A. J., Corrales‐Sánchez, V., Díez-González, L., Cuenca-López, M. D., Šeruga, B., Pandiella, A., & Amir, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095219 · Cited by 168 · see citing works

Nuclear phosphoinositide 3-kinase β controls double-strand break DNA repair

Kumar, A., Fernández-Capetillo, Ó., & Carrera, A. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914242107 · Cited by 165 · see citing works

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Tolcher, A. W., Patnaik, A., Papadopoulos, K. P., Rasco, D. W., Becerra, C. R., Allred, A. J., Orford, K., Aktan, G., Ferron-Brady, G., Ibrahim, N., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2615-5 · Cited by 158 · see citing works

Class II PI3K Functions in Cell Biology and Disease

Gulluni, F., Santis, M. C. D., Margaria, J. P., Martini, M., & Hirsch, E. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.001 · Cited by 152 · see citing works

Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective

Garces, A. E., & Stocks, M. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01492 · Cited by 151 · see citing works

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Garrido-Castro, A. C., Saura, C., Barroso‐Sousa, R., Guo, H., Ciruelos, E., Bermejo, B., Gavilá, J., Serra, V., Prat, A., Paré, L., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01354-y · Cited by 145 · see citing works

Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.

Baselga, J. M., Dent, S. F., Cortés, J., Im, Y., Dieras, V. C., Harbeck, N., Krop, I. E., Verma, S., Wilson, T. R., Jin, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.18_suppl.lba1006 · Cited by 138 · see citing works

Management of toxicity to isoform α-specific PI3K inhibitors

Nunnery, S. E., & Mayer, I. A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz440 · Cited by 137 · see citing works

Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes.

Racker, E., Resnick, R. J., & Feldman, R. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.11.3535 · Cited by 135 · see citing works

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer

Do, K. T., Speranza, G., Bishop, R. J., Khin, S. A., Rubinstein, L., Kinders, R. J., Datiles, M. B., Eugeni, M. A., Lam, M. H., Doyle, L. A., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0212-z · Cited by 133 · see citing works

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non– BRCA1/2 -Mutant Cancers

Yap, T. A., Kristeleit, R. S., Michalarea, V., Pettitt, S. J., Lim, J. S. J., Carreira, S., Roda, D., Miller, R. E., Riisnaes, R., Miranda, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0163 · Cited by 129 · see citing works

High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1

Yellen, P., Saqcena, M., Salloum, D., Feng, J., Preda, A., Xu, L., Rodrik-Outmezguine, V. S., & Foster, D. A. (2011) · Cell Cycle · doi:10.4161/cc.10.22.18124 · Cited by 117 · see citing works

The Enigma of Rapamycin Dosage

Mukhopadhyay, S., Frías, M. A., Chatterjee, A., Yellen, P., & Foster, D. A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0720 · Cited by 114 · see citing works

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer

Smyth, L. M., Tamura, K., Oliveira, M., Ciruelos, E., Mayer, I. A., Sablin, M., Biganzoli, L., Ambrose, H. J., Ashton, J., Barnicle, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3953 · Cited by 113 · see citing works

Vps34 Kinase Domain Dynamics Regulate the Autophagic PI 3-Kinase Complex

Stjepanović, G., Baskaran, S., Lin, M. G., & Hurley, J. H. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.07.003 · Cited by 111 · see citing works

INPP4B: the New Kid on the PI3K Block

Agoulnik, I., Hodgson, M., Bowden, W. A., & Ittmann, M. (2011) · OncoTarget · doi:10.18632/oncotarget.260 · Cited by 110 · see citing works

Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer

du Rusquec, P., Blonz, C., Frenel, J., & Campone, M. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920940939 · Cited by 109 · see citing works

Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes

Chun, S. Y., Johnson, C., Washburn, J. G., Cruz-Correa, M. R., Dang, D. T., & Dang, L. H. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-293 · Cited by 109 · see citing works

“The emerging role of capivasertib in breast cancer”

Andrikopoulou, Α., Chatzinikolaou, S., Panourgias, E. C., Καπαρέλου, Μ., Liontos, M., Dimopoulos, M. A., & Zagouri, F. (2022) · The Breast · doi:10.1016/j.breast.2022.03.018 · Cited by 106 · see citing works

Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer

Zhang, Z., Richmond, A. J., & Yan, C. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137353 · Cited by 105 · see citing works

Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2α Scaffolding Function

Gulluni, F., Martini, M., Santis, M. C. D., Campa, C. C., Ghigo, A., Margaria, J. P., Ciraolo, E., Franco, I., Ala, U., Annaratone, L., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.002 · Cited by 103 · see citing works

Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors

Zhang, Y., Yan, H., Xu, Z., Yang, B., Luo, P., & He, Q. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1663169 · Cited by 101 · see citing works

Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes

Wang, D., Li, C., Zhang, Y., Wang, M., Jiang, N., Lin, X., Li, T., Roberts, T. M., Zhao, J. J., Cheng, H.-L. M., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.07.092 · Cited by 100 · see citing works

The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

Carden, C. P., Stewart, A., Thavasu, P., Kipps, E., Pope, L., Crespo, M., Miranda, S., Attard, G., Garrett, M. D., Clarke, P. A., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0996 · Cited by 97 · see citing works

PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis

Bender, A., Opel, D., Naumann, I., Kappler, R., Friedman, L. S., von Schweinitz, D., Debatin, K., & Fulda, S. (2010) · Oncogene · doi:10.1038/onc.2010.429 · Cited by 96 · see citing works

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

Schram, A. M., Gandhi, L., Mita, M. M., Damstrup, L., Campana, F., Hidalgo, M., Grande, E., Hyman, D. M., & Heist, R. S. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0322-4 · Cited by 96 · see citing works

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors

Brandão, M., Caparica, R., Eiger, D., & de Azambuja, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz280 · Cited by 93 · see citing works

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Turner, N. C., Dent, R. A., O’Shaughnessy, J., Kim, S., Isakoff, S. J., Barrios, C. H., Saji, S., Bondarenko, I., Nowecki, Z. I., Lian, Q., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06450-x · Cited by 92 · see citing works

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Shapiro, G. I., LoRusso, P., Kwak, E., Pandya, S., Rudin, C. M., Kurkjian, C., Cleary, J. M., Pilat, M. J., Jones, S., de Crespigny, A., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00776-6 · Cited by 90 · see citing works

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

Turner, N. C., Alarcon-Rozas, A. E., Armstrong, A. C., Philco, M., Chuken, Y. A. L., Sablin, M., Tamura, K., Villanueva, A. G., Fidalgo, J. A. P., Cheung, S. Y. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz086 · Cited by 89 · see citing works

Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer

Mego, M., Gao, H., Cohen, E. N., Anfossi, S., Giordano, A., Sanda, T., Fouad, T. M., Giorgi, U. D., Giuliano, M., Woodward, W. A., et al. (2016) · Journal of Cancer · doi:10.7150/jca.13098 · Cited by 88 · see citing works

Dysregulated PTEN‐PKB and negative receptor status in human breast cancer

Shi, W., Zhang, X., Pintilie, M., Ma, N., Miller, N. A., Banerjee, D., Tsao, M., Mak, T. W., Fyles, A., & Liu, F. (2003) · International Journal of Cancer · doi:10.1002/ijc.10909 · Cited by 87 · see citing works

Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib

Lara, P. N., Longmate, J., Mack, P. C., Kelly, K. L., Socinski, M. A., Salgia, R., Gitlitz, B. J., Li, T., Koczywas, M., Reckamp, K. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3281 · Cited by 85 · see citing works

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

Konopleva, M. Y., Walter, R. B., Faderl, S. H., Jabbour, E. J., Zeng, Z., Borthakur, G. M., Huang, X., Kadia, T. M., Ruvolo, P. P., Feliu, J. B., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1978 · Cited by 83 · see citing works

The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere

Li, J., Davies, B., Han, S., Zhou, M., Bai, Y., Zhang, J., Xu, Y., Tang, L., Wang, H., Liu, Y.-J., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-241 · Cited by 82 · see citing works

Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235

Hall, C. P., Reynolds, C. P., & Kang, M. H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0114 · Cited by 81 · see citing works

Class I PI 3-kinases: Function and evolution

Kriplani, N., Hermida, M. A., Brown, E. R., & Leslie, N. R. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2015.05.002 · Cited by 81 · see citing works

Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice

Gagliato, D. D. M., Cortés, J., Curigliano, G., Loi, S., Denkert, C., Pérez-García, J. M., & Holgado, E. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.003 · Cited by 80 · see citing works

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations

Zumsteg, Z. S., Morse, N., Krigsfeld, G. S., Gupta, G. P., Higginson, D. S., Lee, N. Y., Morris, L. G. T., Ganly, I., Shiao, S. L., Powell, S. N., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2245 · Cited by 76 · see citing works

Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

Batalini, F., Xiong, N., Tayob, N., Polak, M. M., Eismann, J., Cantley, L. C., Shapiro, G. I., Adalsteinsson, V. A., Winer, E. P., Konstantinopoulos, P. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3045 · Cited by 73 · see citing works

Rapamycin-induced G1 cell cycle arrest employs both TGF-β and Rb pathways

Chatterjee, A., Mukhopadhyay, S., Tung, K. H.-Y., Patel, D., & Foster, D. A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.01.043 · Cited by 70 · see citing works

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

Wang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., Sadek, N., Xiao, M., Zhang, J., Labrie, M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01911-5 · Cited by 66 · see citing works

Targeting Aberrant PI3K/Akt Activation by PI103 Restores Sensitivity to TRAIL-Induced Apoptosis in Neuroblastoma

Opel, D., Naumann, I., Schneider, M., Bertele, D., Debatin, K., & Fulda, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2530 · Cited by 65 · see citing works

Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

Blagden, S. P., Hamilton, A. L., Mileshkin, L., Wong, S., Michael, A., Hall, M., Goh, J. C. H., Lisyanskaya, A. S., DeSilvio, M., Frangou, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2277 · Cited by 65 · see citing works

Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer

Giorgi, U. D., Mego, M., Scarpi, E., Giordano, A., Giuliano, M., Valero, V., Álvarez, R. H., Ueno, N. T., Cristofanilli, M., & Reuben, J. M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919866065 · Cited by 64 · see citing works

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

Pistilli, B., Pluard, T., Urruticoechea, A., Farci, D., Kong, A. H., Bachelot, T., Chan, S. Y. T., Han, H. S., Jerusalem, G., Urban, P., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4596-7 · Cited by 62 · see citing works

Targeting Therapeutic Liabilities Engendered by PIK3R1 Mutations for Cancer Treatment

Cheung, L. W. T., & Mills, G. B. (2016) · Pharmacogenomics · doi:10.2217/pgs.15.174 · Cited by 61 · see citing works

PTEN in Hereditary and Sporadic CancerPreprint

Ngeow, J. Y. Y., & Eng, C. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036087 · Cited by 61 · see citing works

Regulation of 6-phosphofructo-1-kinase activity in ras-transformed rat-1 fibroblasts

Kole, H. K., Resnick, R. J., Van Doren, M., & Racker, E. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90084-v · Cited by 57 · see citing works

Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors

Tsolakos, N., Durrant, T. N., Chessa, T. A. M., Suire, S., Oxley, D., Kulkarni, S., Downward, J., Perišić, O., Williams, R. L., Stephens, L., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803446115 · Cited by 56 · see citing works

ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition

Toulany, M., Minjgee, M., Saki, M. R., Holler, M., Meier, F. E., Eicheler, W., & Rodemann, H. P. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.27311 · Cited by 55 · see citing works

Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses

Fumagalli, C., Ranghiero, A., Gandini, S., Corso, F., Taormina, S. V., Camilli, E. D., Rappa, A., Vacirca, D., Viale, G., Guerini‐Rocco, E., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01345-z · Cited by 54 · see citing works

Power of PTEN/AKT: Molecular switch between tumor suppressors and oncogenes

Xie, Y., Naizabekov, S., Chen, Z., & Tokay, T. (2016) · Oncology Letters · doi:10.3892/ol.2016.4636 · Cited by 52 · see citing works

BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma

Speranza, M. C., Nowicki, M. O., Behera, P., Cho, C., Chiocca, E. A., & Lawler, S. E. (2016) · Scientific Reports · doi:10.1038/srep20189 · Cited by 49 · see citing works

The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)

Gazi, M., Moharram, S. A., Marhäll, A., & Kazi, J. U. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.035 · Cited by 47 · see citing works

A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer

Bang, Y.-J., Kang, Y., Ng, M. C. H., Chung, H. C., Wainberg, Z. A., Gendreau, S. B., Chan, W., Xu, N., Maslyar, D. J., Meng, R. D., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.017 · Cited by 46 · see citing works

PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers

Dumbrava, E. E. I., Call, S. G., Huang, H. J., Stuckett, A. L., Madwani, K., Adat, A., Hong, D. S., Piha-Paul, S. A., Subbiah, V., Karp, D. D., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100230 · Cited by 45 · see citing works

Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models

Wu, X.-H., Zhang, J., Zhen, R., Lv, J., Li, Z., Su, X., Zhu, G., Gavine, P. R., Xu, L., Lu, S., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-180 · Cited by 44 · see citing works

Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines

Ma, B. B. Y., Lui, V. W. Y., Hui, C. W. C., Lau, C. P. Y., Wong, C. H., Hui, E. P., Ng, M. H. L., Tsao, S. W., Li, Y., & Chan, A. T. �. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9896-5 · Cited by 44 · see citing works

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors

Isakoff, S. J., Tabernero, J. M., Molife, L. R., Soria, J., Cervantes, A. M. R., Vogelzang, N. J., Patel, M. R., Hussain, M., Baron, A. D., Argilés, G., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.007 · Cited by 41 · see citing works

Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment

Gianni, C., Palleschi, M., Schepisi, G., Casadei, C., Bleve, S., Merloni, F., Sirico, M., Sarti, S., Cecconetto, L., Menna, G. D., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.882896 · Cited by 38 · see citing works

AKT mutant allele-specific activation dictates pharmacologic sensitivities

Shrestha-Bhattarai, T., Shamu, T., Gorelick, A. N., Chang, M. T., Chakravarty, D., Gavrila, E. I., Donoghue, M. T. A., Gao, J., Patel, S., Gao, S. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29638-1 · Cited by 37 · see citing works

Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC).

Matulonis, U. A., Wulf, G. M., Birrer, M. J., Westin, S. N., Quy, P., Bell‐McGuinn, K. M., Lasonde, B., Whalen, C., Aghajanian, C. A., Solit, D. B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2510 · Cited by 36 · see citing works

Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells.

Fekete, M., Santiskulvong, C., Eng, C., & Dorigo, O. (2012) · PubMed · Cited by 35 · see citing works

Akt inhibitor MK‑2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine

Wang, Z., Luo, G., & Qiu, Z. (2020) · Oncology Letters · doi:10.3892/ol.2020.11300 · Cited by 31 · see citing works

Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer

Yamamoto, N., Fujiwara, Y., Tamura, K., Kondo, S., Iwasa, S., Tanabe, Y., Horiike, A., Yanagitani, N., Kitazono, S., Inatani, M., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0382-3 · Cited by 30 · see citing works

Class III phosphatidylinositol-3-OH kinase controls epithelial integrity through endosomal LKB1 regulation

O’Farrell, F., Lobert, V. H., Sneeggen, M., Jain, A., Katheder, N. S., Wenzel, E. M., Schultz, S. W., Tan, K. W., Brech, A., Stenmark, H., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3631 · Cited by 29 · see citing works

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines

Puglisi, M., Thavasu, P., Stewart, A., Bono, J. S. D., O'Brien, M. E. R., Popat, S., Bhosle, J., & Banerji, U. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.05.008 · Cited by 28 · see citing works

Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells

Perkins, M. R., Grande, S. M., Hamel, A., Horton, H. M., Garrett, T. E., Miller, S. M., Latimer, H. J., Horvath, C. J., Kuczewski, M., Friedman, K. M., et al. (2015) · Blood · doi:10.1182/blood.v126.23.1893.1893 · Cited by 27 · see citing works

mTOR in Lung Neoplasms

Krencz, I., Sebestyén, A., & Khoor, A. (2020) · Pathology and Oncology Research · doi:10.1007/s12253-020-00796-1 · Cited by 24 · see citing works

A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600^E/K mutant advanced melanoma

Algazi, A. P., Rotow, J., Posch, C., Ortiz‐Urda, S., Pelayo, A., Munster, P. N., & Daud, A. (2019) · Pigment Cell &amp; Melanoma Research · doi:10.1111/pcmr.12777 · Cited by 23 · see citing works

Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-β-dependent G1 cell cycle arrest

Yellen, P., Chatterjee, A., Preda, A., & Foster, D. A. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.041 · Cited by 23 · see citing works

A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer

Shore, N. D., Mellado, B., Shah, S. K., Hauke, R. J., Costin, D., Adra, N., Cullberg, M., Teruel, C. F., & Morris, T. (2022) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2022.11.017 · Cited by 23 · see citing works

Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth

Cisse, O., Quraishi, M., Gulluni, F., Guffanti, F., Mavrommati, I., Suthanthirakumaran, M., Oh, L. C. R., Schlatter, J. N., Sarvananthan, A., Broggini, M., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1472-9 · Cited by 21 · see citing works

Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic

Chauhan, A., & Cheson, B. D. (2021) · Cancer Management and Research · doi:10.2147/cmar.s201024 · Cited by 19 · see citing works

Suppression of AKT Phosphorylation Restores Rapamycin-Based Synthetic Lethality in SMAD4-Defective Pancreatic Cancer Cells

LeGendre, O., Sookdeo, A., Dulièpre, S.-A. C., Utter, M., Frías, M. A., & Foster, D. A. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0679 · Cited by 19 · see citing works

FDA approves alpelisib for metastatic breast cancer

(2019) · Case Medical Research · doi:10.31525/cmr-14804bd · Cited by 19 · see citing works

Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors

Thulin, A., Andersson, C., Rönnerman, E. W., Lara, S. D., Chamalidou, C., Schoenfeld, A., Kovács, A., Fagman, H., Enlund, F., & Linderholm, B. K. (2021) · Scientific Reports · doi:10.1038/s41598-021-02903-x · Cited by 18 · see citing works

Alpelisib in the Treatment of Metastatic HR+ Breast Cancer with PIK3CA Mutations

Mavratzas, A., & Marmé, F. (2020) · Future Oncology · doi:10.2217/fon-2020-0464 · Cited by 15 · see citing works

Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).

Cruz, C., Schüler, M., Machiels, J., Hess, D., Paz-Ares, L. G., Awada, A. H., von Moos, R., Steeghs, N., Rodon, J. A., Mesmaeker, P. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.627 · Cited by 15 · see citing works

Testing considerations for phosphatidylinositol‐3‐kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer

Toppmeyer, D., & Press, M. F. (2020) · Cancer Medicine · doi:10.1002/cam4.3278 · Cited by 9 · see citing works

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138 · see citing works

Fluorine in the Pharmaceutical Industry: FDA‐Approved Fluorine‐Containing Drugs in 2024

Du, Y., Bian, Y., Baecker, D., Dhawan, G., Semghouli, A., Kiss, L., Zhang, W., Sorochinsky, A. E., Soloshonok, V. A., & Han, J. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202500662 · Cited by 118 · see citing works

Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies

Ji, Z., Shen, J., Lan, Y., Yi, Q., & Liu, H. (2023) · MedComm · doi:10.1002/mco2.308 · Cited by 68 · see citing works

Targeting PI3K/AKT/mTOR signaling to overcome drug resistance in cancer

Tufail, M., Wan, W., Jiang, C., & Li, N. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111055 · Cited by 68 · see citing works

Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting

Qiang, M., Chen, Z., Liu, H., Dong, J., Gong, K., Zhang, X., Huo, P., Zhu, J., Shao, Y., Ma, J., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1516583 · Cited by 40 · see citing works

Advancement in precision diagnosis and therapeutic for triple-negative breast cancer: Harnessing diagnostic potential of CRISPR-cas & engineered CAR T-cells mediated therapeutics

Nayak, V., Patra, S., Singh, K. R., Ganguly, B., Kumar, D. N., Panda, D., Maurya, G. K., Singh, J., Majhi, S., Sharma, R., et al. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116573 · Cited by 36 · see citing works

Immune checkpoint inhibitors in metastatic melanoma therapy (Review)

Shah, V., Panchal, V. S., Shah, A., Vyas, B., Agrawal, S. P., & Bharadwaj, S. P. (2024) · Medicine International · doi:10.3892/mi.2024.137 · Cited by 36 · see citing works

Inhibitors of the PI3K/AKT/mTOR pathway in human malignancies; trend of current clinical trials

Davoodi‐Moghaddam, Z., Jafari‐Raddani, F., Delshad, M., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05277-x · Cited by 32 · see citing works

The Role of the PI3K/Akt/mTOR Axis in Head and Neck Squamous Cell Carcinoma

Jiang, Q., Xiao, J., Hsieh, Y.-C., Kumar, N., Han, L., Zou, Y., & Li, H. (2024) · Biomedicines · doi:10.3390/biomedicines12071610 · Cited by 32 · see citing works

New insights into the biology of T-cell lymphomas

Iqbal, J., Inghirami, G., & Chan, W. C. (2024) · Blood · doi:10.1182/blood.2023021787 · Cited by 32 · see citing works

The role of ubiquitination and deubiquitination in PI3K/AKT/mTOR pathway: A potential target for cancer therapy

Jin, J., He, J., Li, X., Li, X., & Jin, X. (2023) · Gene · doi:10.1016/j.gene.2023.147807 · Cited by 31 · see citing works

Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers

Shan, K. S., Bonano-Rios, A. M., Theik, N. W. Y., Hussein, A. M., & Blaya, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041973 · Cited by 30 · see citing works

Targeting mitochondrial transporters and metabolic reprogramming for disease treatment

Anselme, M., He, H., Lai, C., Luo, W., & Zhong, S. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06976-4 · Cited by 31 · see citing works

Signaling pathway dysregulation in breast cancer

Ryspayeva, D., Seyhan, A. A., MacDonald, W., Purcell, C., Roady, T. J., Ghandali, M., Verovkina, N., El‐Deiry, W. S., Taylor, M. S., & Graff, S. L. (2025) · Oncotarget · doi:10.18632/oncotarget.28701 · Cited by 30 · see citing works

The PIK3CA gene and its pivotal role in tumor tropism of triple-negative breast cancer

Mallick, S., Duttaroy, A. K., & Dutta, S. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102140 · Cited by 23 · see citing works

Current developments in PI3K-based anticancer agents: Designing strategies, biological activity, selectivity, structure-activity correlation, and docking insight.

Sk, M. A., K., H., Matada, G. S. P., Pal, R., V., M. B., Mounika, S., E, H., P., V. M., & Anjan, D. (2024) · Bioorganic chemistry (Print) · doi:10.1016/j.bioorg.2024.108011 · Cited by 20 · see citing works

Tailored therapies for triple-negative breast cancer: current landscape and future perceptions

Khan, Y., Rizvi, S., Raza, A., Khan, A., Hussain, M. S., Khan, N. U., Alshammari, S. O., Alshammari, Q. A., Alshammari, A., & Ellakwa, D. E. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03896-4 · Cited by 20 · see citing works

Network Pharmacology, Molecular Docking and Molecular Dynamics Studies to Predict the Molecular Targets and Mechanisms of Action of Melissa officinalis Phytoconstituents in Type-2 Diabetes Mellitus

Ononamadu, C. J., Ahmed, Z. B., & Seidel, V. (2025) · Plants · doi:10.3390/plants14182828 · Cited by 19 · see citing works

Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care

Moore, H., Goncalves, M. D., Johnston, A. M., Mayer, E. L., Rugo, H. S., Gradishar, W. J., Zylla, D. M., & Bergenstal, R. M. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.09.017 · Cited by 16 · see citing works

NEW DRUGS ON THE PHARMACEUTICAL MARKET CONTAINING FLUORINE AND RESIDUES OF TAILOR-MADE AMINO ACIDS

Han, J., Wzorek, A., Dhawan, G., Zhang, W., Sorochinsky, A. E., Baecker, D., Ono, T., Klika, K. D., & Soloshonok, V. A. (2024) · Ukrainian Chemistry Journal · doi:10.33609/2708-129x.90.9.2024.31-56 · Cited by 16 · see citing works

Preclinical assessment of the PI3Kα selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in human

Salphati, L., Pang, J., Plise, E. G., Cheong, J., Braun, M., Friedman, L. S., Hong, R., Jaochico, A., Johnson, R., Liu, N., et al. (2024) · Xenobiotica · doi:10.1080/00498254.2024.2415103 · Cited by 14 · see citing works

CHIRAL, FLUORINE-CONTAINING PHARMACEUTICALS

Han, J., Wzorek, A., Dhawan, G., Zhang, W., Sorochinsky, A. E., Baecker, D., Ono, T., Klika, K. D., & Soloshonok, V. A. (2025) · Ukrainian Chemistry Journal · doi:10.33609/2708-129x.91.2.2025.55-90 · Cited by 14 · see citing works

Emerging Approaches for Studying Lipid Dynamics, Metabolism, and Interactions in Cells

Luan, L., Frederick, N. P., & Baskin, J. M. (2025) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-083024-110827 · Cited by 14 · see citing works

Progress in Precision Medicine for Head and Neck Cancer

Vakili, S., Behrooz, A. B., Whichelo, R., Fernandes, A. R., Emwas, A.-H. M., Jaremko, M., Markowski, J., Łoś, M., Ghavami, S., & Vitorino, R. M. P. (2024) · Cancers · doi:10.3390/cancers16213716 · Cited by 13 · see citing works

Wortmannin Inhibits Cell Growth and Induces Apoptosis in Colorectal Cancer Cells by Suppressing the PI3K/AKT Pathway

Bani, N., Rahmani, F., Shakour, N., Amerizadeh, F., Khalili‐Tanha, G., Khazaei, M., Hassanian, S. M., Kerachian, M. A., Abbaszadegan, M. R., Mojarad, M., et al. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206296355240325113920 · Cited by 12 · see citing works

Targeting hematological malignancies with isoxazole derivatives

Majirská, M., Pilátová, M. B., Kudlicková, Z., Vojtek, M., & Diniz, C. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104059 · Cited by 12 · see citing works

Targeting the PI3K Pathway: Advancements and Achievements in Breast Cancer Therapy

Dinesh, B. G. H., Bandral, S. K., Sadashivappa, N. M., Ganjipete, S., Ammunje, D. N., Kunjiappan, S., Theivendren, P., Jays, J., & Pavadai, P. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128357976250122042633 · Cited by 12 · see citing works

Structural Investigations of Interactions between the Influenza a Virus NS1 and Host Cellular Proteins

Blake, M. E., Kleinpeter, A. B., Jureka, A. S., & Petit, C. M. (2023) · Viruses · doi:10.3390/v15102063 · Cited by 12 · see citing works

Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targets

Pichler, A., Amador, C., Fujimoto, A., Takeuchi, K., de Jong, D., Iqbal, J., & Staber, P. B. (2024) · Histopathology · doi:10.1111/his.15376 · Cited by 11 · see citing works

The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers

Molefi, T., Mabonga, L., Hull, R., Mwazha, A., Sebitloane, M., & Dlamini, Z. (2025) · Cells · doi:10.3390/cells14050382 · Cited by 11 · see citing works

Unraveling the Role of Tumor-Infiltrating Immune Cells in Head and Neck Squamous Cell Carcinoma: Implications for Antitumor Immune Responses and Immunotherapy

Benítez, P. C. A., Fusco, M., Amorín, R., Picón, C. R., Piccioni, F., Victoria, L., Rizzo, M., & Malvicini, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136337 · Cited by 11 · see citing works

Polymeric Nanoparticles Potentiate the Anticancer Activity of Novel PI3Kα Inhibitors Against Triple-Negative Breast Cancer Cells

Sunoqrot, S., Abusulieh, S., & Sabbah, D. A. (2024) · Biomedicines · doi:10.3390/biomedicines12122676 · Cited by 10 · see citing works

Molecular mechanisms and diagnostic innovations in HPV-associated head and neck squamous cell carcinomas: Insights into integration, epigenetic modifications, and biomarker applications

Shanmugam, G., Jeyaraj, G., & Sarkar, K. (2024) · Oral Oncology Reports · doi:10.1016/j.oor.2024.100710 · Cited by 10 · see citing works

Molecular Docking Appraisal of Pleurotus ostreatus Phytochemicals as Potential Inhibitors of PI3K/Akt Pathway for Breast Cancer Treatment

Effiong, M. E., Bella-Omunagbe, M., Afolabi, I. S., & Chinedu, S. N. (2025) · Bioinformatics and Biology Insights · doi:10.1177/11779322251316864 · Cited by 10 · see citing works

Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer

Melino, M., Tu, W. J., Bielefeldt‐Ohmann, H., Proctor, M. A., Ahuja, T., Vandermeide, J., Bain, A. L., Nallan, G., Goh, S. L., Prasanna, T., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0693 · Cited by 10 · see citing works

Shared molecular, cellular, and environmental hallmarks in cardiovascular disease and cancer: Any place for drug repurposing?

Avolio, E., Bassani, B., Campanile, M., Mohammed, K. A. K., Muti, P. C., Bruno, A., Spinetti, G., & Madeddu, P. R. (2024) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100033 · Cited by 9 · see citing works

Current and Emerging Therapies for Targeting the ERK1/2 & PI3K Pathways in Cancer

Abizadeh, E., Berglas, E., Abizadeh, A., Glatman, J., Lavi, A. B., Spivak, M., Sapir, T., & Shifteh, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178696 · Cited by 11 · see citing works

Anticancer effects of alpelisib on PIK3CA-mutated canine mammary tumor cell lines

Yeom, J., Cho, Y., Ahn, S., & Jeung, S.-Y. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1279535 · Cited by 8 · see citing works

Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnesses

Nikanjam, M., Wells, K., Kato, S., Adashek, J. J., Block, S., & Kurzrock, R. (2024) · Med · doi:10.1016/j.medj.2024.04.008 · Cited by 8 · see citing works

Vertical targeting of the PI3K/AKT pathway at multiple points is synergistic and effective for non-Hodgkin lymphoma

Kupcová, K., Seňavová, J., Jura, F., Herman, V., Rajmonová, A., Pacheco‐Blanco, M., Chrbolkova, T., Hamová, I., Davis, R. E., & Havránek, O. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00568-6 · Cited by 8 · see citing works

Radiogenomic Landscape of Metastatic Endocrine-Positive Breast Cancer Resistant to Aromatase Inhibitors

Khanyile, R., Chipiti, T., Hull, R., & Dlamini, Z. (2025) · Cancers · doi:10.3390/cancers17050808 · Cited by 7 · see citing works

Non-coding transcriptome profiles in clear-cell renal cell carcinoma

Tesařová, T., Fiala, O., Hora, M., & Václavíková, R. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00926-3 · Cited by 6 · see citing works

Signaling pathway regulators in preimplantation embryos

Karami, N., Taei, A., Eftekhari‐Yazdi, P., & Hassani, F. (2024) · Journal of Molecular Histology · doi:10.1007/s10735-024-10338-7 · Cited by 6 · see citing works

Dual Targeting of MEK1 and Akt Kinase Identified SBL‐027 as a Promising Lead Candidate to Control Cell Proliferations in Gastric Cancer

Alghamdi, M. A., & Deshpande, H. (2025) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2716 · Cited by 6 · see citing works

Unraveling the interplay: exploring signaling pathways in pancreatic cancer in the context of pancreatic embryogenesis

Swain, S., Narayan, R. K., & Mishra, P. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1461278 · Cited by 5 · see citing works

Integration of Consensus‐Based Pharmacophore Mapping and Molecular Docking in Sequential Virtual Screening: Toward the Discovery of Novel PI3Kγ Inhibitors

Yu, X., Yuan, S., Jia, L., Cai, Y., Chen, Y., Jin, J., Xu, L., Li, Y., & Zhu, J. (2024) · ChemistrySelect · doi:10.1002/slct.202403520 · Cited by 5 · see citing works

Targeted small molecule therapy and inhibitors for lymphoma

Wang, Z., Zheng, X., Rao, G., & Zheng, Q. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2359893 · Cited by 5 · see citing works

Pi Ji Pills reshape the pancreatic cancer immune microenvironment and enhance the efficacy of gemcitabine through dual mechanisms of PI3K/AKT pathway blockade and NETs inhibition

Zhang, C., Jiang, X., Li, Y., Liu, F., Shen, Q., Lin, H., & Pang, B. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120579 · Cited by 4 · see citing works

Recent advancements in therapeutic biomarkers, associated challenges and considerations to overcome these challenges in prostate cancer (Review)

Gandupalli, L., Bhowmik, D., Jyotishi, C., & Gupta, R. (2025) · World Academy of Sciences Journal · doi:10.3892/wasj.2025.313 · Cited by 4 · see citing works

Gene expression analysis reveals mir-29 as a linker regulatory molecule among rheumatoid arthritis, inflammatory bowel disease, and dementia: Insights from systems biology approach

Sasikumar, D. S. N., & Sundararajan, V. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316584 · Cited by 4 · see citing works

PI3Kγ in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target

Luo, Q., Fortune, A., & Lane, A. A. (2025) · Blood · doi:10.1182/blood.2024027376 · Cited by 3 · see citing works

PI5P4Kα promotes glucose and iron acquisition to support metabolic fitness in pancreatic cancer

Arora, G. K., Loughran, R. M., Ly, K., Galapate, C. M., Lope, A. L., Anderson, T. R., Zhang, C. Y., Grenier, S. F., Li, L., Crabtree, S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116199 · Cited by 3 · see citing works

Discovery, Optimization, and Anticancer Activity of Lipid-Competitive Pleckstrin Homology Domain-Containing Family A Inhibitors

Frederick, N. P., Cao, X., Jin, Y., Lombardo, A. T., & Baskin, J. M. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01338 · Cited by 3 · see citing works

Use of 3′ Rapid Amplification of cDNA Ends (3′ RACE)-Based Targeted RNA Sequencing for Profiling of Druggable Genetic Alterations in Urothelial Carcinomas

Mitiushkina, N. V., Tiurin, V. I., Алексеевна, А. А., Bordovskaya, N. A., Nalivalkina, E. A., Терина, Д. М., Беркут, М. В., Шестакова, А. Д., Syomina, M. V., Kuligina, E. S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212126 · Cited by 3 · see citing works

Piperazine-Substituted Pyranopyridines Exhibit Antiproliferative Activity and Act as Inhibitors of HBV Virion Production

Buloyan, S. A., Harutyunyan, A. S., Gasparyan, H. V., Sakeyan, A., Shahkhatuni, A. A., Zakirova, N. F., Yusubalieva, G. M., Kirillov, I., Тимофеевна, Ф. И., Solyev, P. N., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26093991 · Cited by 3 · see citing works

Comment l’activité physique pourrait-elle réduire le risque de survenue et de récidive des cancers du sein ?

Meneu, A., Lavoué, V., Guillermet, S., Lévêque, J., Mathelin, C., & Brousse, S. (2024) · Gynécologie Obstétrique Fertilité & Sénologie · doi:10.1016/j.gofs.2024.01.004 · Cited by 3 · see citing works

Modeling the management of patients with human epidermal growth factor receptor 2-positive breast cancer with liquid biopsy: the future of precision medicine

Nicolò, E., Gianni, C., Curigliano, G., Reduzzi, C., & Cristofanilli, M. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001082 · Cited by 3 · see citing works

TP53 Mutations and Phosphatidylinositol 3-Kinase/AKT Pathway Alterations Are Key Determinants of Breast Cancer Outcome Independent of Subtype and Stage

Zwimpfer, T. A., Heidinger, M., Coelho, R., Stiegeler, N., Schwab, F. D., Montavon, C., Eller, R. S., Maggi, N., Loesch, J. M., Vetter, M. H. F., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00767 · Cited by 3 · see citing works

Liquid biopsy to tailor the treatment of advanced hormone receptor-positive breast cancer in the era of novel endocrine agents and CDK4/6-inhibitors

Seguí, E., & Schettini, F. (2023) · Annals of Translational Medicine · doi:10.21037/atm-23-1804 · Cited by 3 · see citing works

PI3Kδ as a Novel Therapeutic Target for Aggressive Prostate Cancer

Wang, B., Lucero, A., Ha, S., & Yarmohammadi, R. (2025) · Cancers · doi:10.3390/cancers17101610 · Cited by 2 · see citing works

PI3K inhibitors: Efficacy in diverse cancer forms

Kianfar, E., Alrudainy, A. M., Al-Zaalan, A. R., Kadhum, W. R., & Jassim, A. Y. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.101028 · Cited by 2 · see citing works

Transcription factor targeting strategies in cancer: mechanisms, challenges and cutting-edge progress

Chen, H., Fu, R., & Wu, Z. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01877-8 · Cited by 2 · see citing works

[S100A10 promotes proliferation and invasion of lung adenocarcinoma cells by activating the Akt-mTOR signaling pathway].

Wang, H., Sun, Z., Zhao, W., & Geng, B. (2023) · PubMed Central · doi:10.12122/j.issn.1673-4254.2023.05.08 · Cited by 2 · see citing works

Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications

Hashemi, M., Fard, A. A., Pakshad, B., Asheghabadi, P. S., Hosseinkhani, A., Hosseini, A. S., Moradi, P., Niye, M. M., Najafi, G., Farahzadi, M., et al. (2024) · Non-coding RNA Research · doi:10.1016/j.ncrna.2024.11.006 · Cited by 3 · see citing works

Altered PI3K/AKT/mTOR Signaling Pathway and Cancer Stem Cells

Ertay, A. (2024) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-031-74842-4_5 · Cited by 2 · see citing works

The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer

Melosky, B. L., Juergens, R. A., Banerji, S. O., Sacher, A. G., Wheatley‐Price, P., Snow, S. L., Tsao, M., Leighl, N. B., Martins, I., Cheema, P. K., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241308784 · Cited by 2 · see citing works

Molecular biology of the novel anticancer medications: a focus on kinases inhibitors, biologics and CAR T-cell therapy

Abdo, E.-L., Ajib, I., Mounzer, J. E., Husseini, M., Kalaoun, G., Matta, T.-M., Mosleh, R., Nasr, F., Richani, N., Khalil, A., et al. (2025) · Inflammation Research · doi:10.1007/s00011-025-02008-5 · Cited by 2 · see citing works

Discovery of a selective PI3Kα inhibitor via structure-based virtual screening for targeted colorectal cancer therapy

Albassam, H., Almutairi, O., Alnasser, M., Altowairqi, F., Almutairi, F., & Alobid, S. E. (2025) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2025.2468852 · Cited by 3 · see citing works

FHL2 facilitates LUSC growth and therapy resistance through PI3K/AKT/mTOR activation

Zhang, L., Wang, D., Zeng, L., Chen, S., Li, K., Yuan, T., Wang, J., Ma, X., Zhu, S., & Wu, Y. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110332 · Cited by 2 · see citing works

Pan-Cancer Analyses of Shared and Distinct Gene Expression in 17 Cancers: Rethinking Cancer Classification and Moving Beyond “One Drug, One Disease” Paradigm of Pharmaceutical Innovation

Göv, E., & Gul, A. (2025) · OMICS A Journal of Integrative Biology · doi:10.1177/15578100251387873 · Cited by 2 · see citing works

Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies

Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1 · see citing works

DiWB‐1: A Luteinizing Hormone Releasing Hormone (LHRH)‐Targeted Peptide‐Drug Conjugate (PDC) With Enhanced Tumor Selectivity and PI3K Inhibition Efficacy

Zhang, C., Zhong, H., Li, X., Xing, Z., Li, S., Yu, R., & Deng, X. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70021 · Cited by 1 · see citing works

Selective PI3Kγ inhibition attenuates chemotherapy-induced intestinal mucositis without compromising the anticancer properties of irinotecan

Cajado, A. G., Lopes, M. H. S., Rangel, G. D. F. P., Ferreira, K. Q., Choquenaira-Quispe, C., Silva, R. L., Ferreira, L. M. M., Nobre, L. M. S., da Silva, J. M. R., Quintela, L. C. S., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178165 · Cited by 1 · see citing works

Deciphering deubiquitinating enzyme Ataxin-3 as an emerging target for cancer intervention

Khan, A., & Bhatt, L. K. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148113 · Cited by 1 · see citing works

Case Report: From teratoma to adenocarcinoma: molecular insights into somatic-type malignancy in testicular germ cell tumors - two case reports and review of the literature

Rozsvai, T., Pósfai, B., Torday, L., Borzási, E., Lázár, G., Oláh, J., Radics, B., Király, I. E., Papos, I., Balázsfi, M., et al. (2025) · Pathology & Oncology Research · doi:10.3389/pore.2025.1612227 · Cited by 1 · see citing works

Current Status of Molecularly Targeted Therapeutics in Blood Cancers

Kumala, C., Vu, L., & Fandy, T. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110512 · Cited by 1 · see citing works

PI3Kα inhibitors: structural advances, synthesis strategies, and anticancer potential

Swati, Kumar, S., Chander, S., Wadhwa, P. K., Ghnaim, A. O., Bhandare, R. R., & SHAIK, A. B. (2025) · Journal of Saudi Chemical Society · doi:10.1007/s44442-025-00047-5 · Cited by 1 · see citing works

From Signaling Pathways to Combination Therapy: Bioactive Compounds against Cancer Stem Cells

Psvv, C., Pai, N. S., Naik, N. A., Thuyyath, N., Joseph, A., Danthuluri, S., Palanki, S. S., Patel, N., & Lavudi, K. (2026) · Stem Cell Reviews and Reports · doi:10.1007/s12015-026-11057-0 · Cited by 1 · see citing works

Fasting-mimicking diets as a strategy to reprogram tumor metabolism: a systematic review

Pereira, I. C., Martins, J. A., de Sousa, D. J. M., Neres, M. S. D. O., LIMA, R. S. P., Sousa, J. D. S., Monteiro, R. L., da Silva, F. C. C., Severo, J. S., & Torres‐Leal, F. L. (2026) · European Journal of Nutrition · doi:10.1007/s00394-026-03891-2 · Cited by 1 · see citing works

Computational design and evaluation of novel thienopyrimidine PI3Kδ inhibitors for diffuse large b-cell lymphoma: QSAR, docking, molecular dynamics, and density functional theory studies

Isah, J. J., Uzairu, A., Uba, S., & Ibrahim, M. T. (2026) · Current Pharmaceutical Analysis · doi:10.1016/j.cpan.2026.03.005 · Cited by 1 · see citing works

Bleomycin ElectroScleroTherapy (BEST): mechanistic parallels to electrochemotherapy, experimental models, and unresolved questions

Lisec, B., Čemažar, M., Muir, T., Omerzel, M., Jesenko, T., Markelc, B., Grošelj, A., Dežman, R., Štabuc, M., Kuhelj, D., et al. (2026) · Radiology and Oncology · doi:10.2478/raon-2026-0017 · Cited by 1 · see citing works

The application of nanoparticle-mediated siRNA delivery systems in ovarian cancer

Qian, X., Yu, Y., Zhang, Y., Dou, Z., Gao, C., & Han, Y. (2026) · Cancer Gene Therapy · doi:10.1038/s41417-026-01020-z · Cited by 1 · see citing works

QSAR-based design and computational evaluation of thieno[2,3-d]pyrimidine derivatives as potential PI3Kα inhibitors

Sivaraman, B., & Muthukumaradoss, K. (2026) · Chemical Papers · doi:10.1007/s11696-026-04856-9 · Cited by 1 · see citing works

Role and Future Directions of PI3K Inhibitors in Cancer Treatment

郝, 思. (2023) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2023.112013

Resistance to Endocrine Therapy in Breast Cancer

Demetriou, D., Khanyile, R., Mbita, Z., & Dlamini, Z. (2024) · Springer eBooks · doi:10.1007/978-3-031-52860-6_5

Design and Synthesis of Luteinizing Hormone Releasing Hormone (Lhrh)-Derived Peptide Conjugates with Pi3k Inhibitor for Enhanced Tumor SelectivityPreprint

Zhang, C., Zhong, H., Li, X., Xing, Z., Li, S., Yu, R., & Deng, X. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4988517

Emerging treatment approaches for colorectal cancer treatment resistance

Mabonga, L., Fourie, R. L., Kappo, A. P., Lyantagaye, S., & Dlamini, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-33475-7.00001-9

WITHDRAWN: Tumor Microenvironment In Head And Neck Cancer: Insights From SpheroidsPreprint

Rao, A., Das, U., Ghodeswar, A., & Chaturvedi, R. (2024) · Research Square · doi:10.21203/rs.3.rs-5551946/v1

Breast Cancer: Epidemiology, Symptoms, Risk Factors, Pathogenesis, Classification, Current Treatments and Various Approaches in Nano-formulations

Kumar, N., Balram, B., Singh, G., Dushyant, Narwal, S., & Dhingra, A. K. (2025) · Current Cancer Therapy Reviews · doi:10.2174/0115733947344495250131171240

Targeting RAS and associated proteins

Müller, M. P., Goody, R. S., & Rauh, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00008-x

A shorter and alternative route to duvelisib: Application in scale-up synthesis

Buddepu, S. R., Venkateshwarlu, R., Suresh, G., Moturu, K. M. V. R., Siddaiah, V., & Pal, M. (2025) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2025.101713

WITHDRAWN: Tumor Microenvironment In Head And Neck Cancer: Insights From SpheroidsPreprint

Rao, A., Das, U., Ghodeswar, A., & Chaturvedi, R. (2025) · Research Square · doi:10.21203/rs.3.rs-5551946/v2

Synthesis and anti-cancer biological evaluation of a novel protoapigenone analogue, WYC-241

Chu, P., Pan, Y., Hsu, W.-Y., Chuang, D., Yang, J., Chen, G., Jang, Y., & Wu, Y. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00349k

Targeting the tumor microenvironment in colorectal cancer: the effect of Rapamycin on angiogenesis, apoptosis, and STAT5A/TORC1 signaling

Mansouri, A., Yaghmaei, P., Ghobeh, M., & Kadivar, M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10995-1

High-Flow and Low-Flow Cerebrovascular Malformations Syndromes Associated With Klippel–Trénaunay and Parkes–Weber Syndromes. A Systematic Review

Palermo, M., Olivi, A., & Sturiale, C. L. (2025) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2025.09.007

Identification of 2-(piperazine _1_yl) _H_benzo[d] imidazole derivatives as a potent EGFR inhibitor by Virtual Screening and Molecular Dynamic Simulation

Jasim, S., Tawfeeq, A. A., Al-hachami, W., & Faisal, M. (2026) · Turkish computational and theoretical chemistry/Turkish computational and theoretical chemistry : · doi:10.33435/tcandtc.1632516

Phosphoinositol-3-kinase (PI3K) inhibitors based on 1,3,5-triazine derivatives for targeted antitumor therapy

Chernov, I. S., Popova, Е. А., Protas, A. V., Molchanov, O. E., Sharoyko, V. V., & Semenov, K. N. (2025) · The Scientific Notes of the Pavlov University · doi:10.24884/1607-4181-2025-32-3-42-52

Current landscape and recent developments of PI3K/AKT/mTOR targeted inhibitors for breast carcinoma

Rana, N., Deval, Singh, H., Garg, A., Monika, Tiwari, R., & Sharma, S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109430

LETROZOLE IMPROVES PROGRESSION-FREE SURVIVAL OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCER TREATED WITH PEGYLATED LIPOSOMAL DOXORUBICIN AND MAGNETOTHERMY

Loboda, A. D., Movchan, O. V., Смоланка, І. І., Dumanskiy, Y. V., O., L. A., Ivankova, O. M., & Dosenko, I. (2025) · Experimental Oncology · doi:10.15407/exp-oncology.2025.03.356

Kinase Chemical Probes and Beyond

Tredup, C., & Müller, S. (2026) · Kinases and Phosphatases · doi:10.3390/kinasesphosphatases4010005

PI3K and cancer: lessons, challenges and opportunities

Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,716 · see citing works

Targeting PI3K/mTOR signaling in cancer

(2014) · Frontiers research topics · doi:10.3389/978-2-88919-244-1 · Cited by 2 · see citing works

Targeting PI3K/Akt signal transduction for cancer therapy

He, Y., Sun, M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,996 · see citing works

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

Yu, L., Wei, J., & Liu, P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 785 · see citing works

A Review on Cancer, Cause of Cancer and Treatment: Role of PIK3 Pathway on Cancer

Choudhary, M. L., & Sisodia, D. S. S. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.13995587